Friday, 16 October 2026European Markets

LHYFE Stock Impressive Rise On Wednesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with lhyfe (lhyfe.pa) jumping 15.76% to €5.40 on wednesday while cac 40 fell 0.27% to €7,656.75.

lhyfe's last close was €4.66, 50.43% under its 52-week high of €9.40.

about lhyfe

lhyfe sa, a renewable energy company, designs, installs, and operates green hydrogen production units in france. the company operates 93 projects. it serves local authorities, industries, transport and logistics, and fuel distribution. the company was founded in 2017 and is headquartered in nantes, france.

earnings per share

as for profitability, lhyfe has a trailing twelve months eps of €-0.47.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -21.12%.

revenue growth

year-on-year quarterly revenue growth grew by 39.7%, now sitting on 680k for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, lhyfe's stock is considered to be oversold (<=20).

yearly top and bottom value

lhyfe's stock is valued at €5.40 at 21:35 est, way below its 52-week high of €9.40 and way higher than its 52-week low of €2.83.

volume

today's last reported volume for lhyfe is 136096 which is 370.88% above its average volume of 28902.

more news about lhyfe (lhyfe.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com